Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nuvation Bio (NUVB) Shares Outstanding (2023 - 2025)

Nuvation Bio (NUVB) has disclosed Shares Outstanding for 3 consecutive years, with $1.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Shares Outstanding fell 99.7% to $1.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.0 million, a 99.7% decrease, with the full-year FY2025 number at $1.0 million, down 99.7% from a year prior.
  • Shares Outstanding was $345.5 million for Q4 2025 at Nuvation Bio, up from $341.8 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $345.5 million in Q4 2025 to a low of $851202.0 in Q2 2024.
  • A 3-year average of $132.5 million and a median of $1.0 million in 2023 define the central range for Shares Outstanding.
  • Biggest YoY gain for Shares Outstanding was 34023.36% in 2025; the steepest drop was 99.7% in 2025.
  • Nuvation Bio's Shares Outstanding stood at $1.0 million in 2023, then surged by 33583.79% to $336.8 million in 2024, then plummeted by 99.7% to $1.0 million in 2025.
  • Per Business Quant, the three most recent readings for NUVB's Shares Outstanding are $1.0 million (Q4 2025), $341.8 million (Q3 2025), and $341.2 million (Q2 2025).